Clinically Guided Warfarin Dose Versus Genotyping In Early Achievement Of Stable Anticoagulant Effect Of Warfarin

Objective To determine efficacy and safety of genotype and clinically guided dosing of warfarin in patients with atrial fibrillation, deep-vein thrombosis, and pulmonary embolism within the first five days after the introduction of therapy.

Saved in:
Bibliographic Details
Published inClinical therapeutics Vol. 38; no. 10; p. e10
Main Authors Makar-Ausperger, K, Bozina, N, Erdeljic Turk, V, Likic, R, Radacic Aumiler, M, Ganoci, L, Francetic, I
Format Journal Article
LanguageEnglish
Published United States Elsevier Limited 01.10.2016
Subjects
Anticoagulants
Cardiac arrhythmia
Embolisms
Genotype & phenotype
Internal Medicine
Medical Education
Pharmaceutical industry
Thrombosis
Online AccessGet full text

Cover

More Information
Summary:Objective To determine efficacy and safety of genotype and clinically guided dosing of warfarin in patients with atrial fibrillation, deep-vein thrombosis, and pulmonary embolism within the first five days after the introduction of therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2016.07.108